In this Issue:
EBUS-TBNA in the diagnostic and staging strategy
AZD9291 highly active in EGFR-resistant NSCLC
Rociletinib promising in EGFR-mutated NSCLC
Crizotinib effective in ROS1-rearranged NSCLC
Vorinostat in advanced malignant pleural mesothelioma
Cisplatin/etoposide vs carboplatin/ paclitaxel in advanced NSCLC
Pembrolizumab promising in advanced NSCLC
Nivolumab active in advanced, refractory, squamous NSCLC
Necitumumab disappoints in stage IV non-squamous NSCLC
Alisertib shows encouraging activity in SCLC
Please login below to download this issue (PDF)